8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Apr 27, 2026·SEC
Mirum Pharmaceuticals, Inc.(MIRM)Earnings, Financials & Key Ratios
MIRM•NASDAQ
$110.08
$5.53B mkt cap·Price updated May 6, 2026
AboutMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.Show more
- Revenue$521M+54.7%
- EBITDA$2M+103.3%
- Net Income-$23M+73.4%
- EPS (Diluted)-0.47+74.6%
- Gross Margin80.71%+6.5%
- EBITDA Margin0.4%+102.1%
- Operating Margin-4.25%+83.7%
- Net Margin-4.48%+82.8%
- ROE-8.65%+76.7%
- ROIC-5.04%+77.3%
- Debt/Equity1.02-27.9%
- Interest Coverage-0.49+90.4%
MIRM Key Insights
Mirum Pharmaceuticals, Inc. (MIRM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 25.7%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Expensive at 17.6x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MIRM Price & Volume
Mirum Pharmaceuticals, Inc. (MIRM) stock price & volume — 10-year historical chart
Loading chart...
MIRM Growth Metrics
Mirum Pharmaceuticals, Inc. (MIRM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years89.13%
TTM8.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-932.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-745.9%
Return on Capital
10 Years-36.41%
5 Years-33.41%
3 Years-15.12%
Last Year-3.75%
MIRM Recent Earnings
Mirum Pharmaceuticals, Inc. (MIRM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 7/12 qtrs (58%)
Q1 2026Latest
Feb 25, 2026EPS
$0.11
Est $0.02
-650.0%
Revenue
$149M
Est $143M
+4.5%
Q4 2025
Nov 4, 2025EPS
$0.05
Est $0.10
+150.0%
Revenue
$133M
Est $141M
-5.6%
Q3 2025
Aug 6, 2025EPS
$0.12
Est $0.31
+61.3%
Revenue
$128M
Est $130M
-1.8%
Q2 2025
May 7, 2025EPS
$0.30
Est $0.39
+23.1%
Revenue
$112M
Est $98M
+13.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.11vs $0.02-650.0% | $149Mvs $143M+4.5% |
| Q4 2025 | Nov 4, 2025 | $0.05vs $0.10+150.0% | $133Mvs $141M-5.6% |
| Q3 2025 | Aug 6, 2025 | $0.12vs $0.31+61.3% | $128Mvs $130M-1.8% |
| Q2 2025 | May 7, 2025 | $0.30vs $0.39+23.1% | $112Mvs $98M+13.4% |
Based on last 12 quarters of dataView full earnings history →
MIRM Peer Comparison
Mirum Pharmaceuticals, Inc. (MIRM) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% |
Compare MIRM vs Peers
Mirum Pharmaceuticals, Inc. (MIRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MIRM Income Statement
Mirum Pharmaceuticals, Inc. (MIRM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 19.14M | 77.06M | 186.37M | 336.89M | 521.31M | 409.73M |
| Revenue Growth % | - | - | - | - | 302.66% | 141.85% | 80.76% | 54.74% | 8.04% |
| Cost of Goods Sold | 0 | 324K | 623K | 1.9M | 12.37M | 47.04M | 81.64M | 100.58M | 832.4M |
| COGS % of Revenue | - | - | - | 9.94% | 16.06% | 25.24% | 24.23% | 19.29% | - |
| Gross Profit | 0▲ 0% | -324K▲ 0% | -623K▼ 92.3% | 17.23M▲ 2866.5% | 64.69M▲ 275.3% | 139.34M▲ 115.4% | 255.25M▲ 83.2% | 420.73M▲ 64.8% | -422.68M▲ 0% |
| Gross Margin % | - | - | - | 90.06% | 83.94% | 74.76% | 75.77% | 80.71% | -103.16% |
| Gross Profit Growth % | - | - | -92.28% | 2866.45% | 275.33% | 115.4% | 83.19% | 64.83% | - |
| Operating Expenses | 2.92M | 54.74M | 103.67M | 190.65M | 195.91M | 248.49M | 342.85M | 443.21M | 533.7M |
| OpEx % of Revenue | - | - | - | 996.18% | 254.22% | 133.33% | 101.77% | 85.02% | - |
| Selling, General & Admin | 585K | 11.75M | 22.69M | 59.22M | 89.07M | 145.88M | 202.22M | 257.03M | 295.65M |
| SG&A % of Revenue | - | - | - | 309.44% | 115.58% | 78.27% | 60.03% | 49.3% | - |
| Research & Development | 2.33M | 42.99M | 81.61M | 131.43M | 106.84M | 102.61M | 140.63M | 186.18M | 238.04M |
| R&D % of Revenue | - | - | - | 686.74% | 138.64% | 55.06% | 41.74% | 35.71% | - |
| Other Operating Expenses | 0 | -21K | -623K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.92M▲ 0% | -54.74M▼ 1777.3% | -104.3M▼ 90.5% | -173.41M▼ 66.3% | -131.22M▲ 24.3% | -109.15M▲ 16.8% | -87.61M▲ 19.7% | -22.14M▲ 74.7% | -796.42M▲ 0% |
| Operating Margin % | - | - | - | -906.12% | -170.28% | -58.57% | -26% | -4.25% | -194.38% |
| Operating Income Growth % | - | -1777.33% | -90.52% | -66.27% | 24.33% | 16.82% | 19.74% | 74.73% | - |
| EBITDA | 1.46M | -54.42M | -103.67M | -172.44M | -127.98M | -98.33M | -63.98M | 2.11M | -778.23M |
| EBITDA Margin % | - | - | - | -901.02% | -166.08% | -52.76% | -18.99% | 0.4% | -189.94% |
| EBITDA Growth % | - | -3832.44% | -90.51% | -66.33% | 25.78% | 23.17% | 34.93% | 103.29% | -1387.89% |
| D&A (Non-Cash Add-back) | 4.37M | 324K | 623K | 975K | 3.24M | 10.83M | 23.63M | 24.24M | 18.19M |
| EBIT | -17.33M | -52.53M | -102.93M | -66.36M | -126.09M | -147.32M | -72.6M | -7.04M | -237K |
| Net Interest Income | 0 | 2.23M | 1.22M | -17.22M | -12.12M | -1.37M | -519K | -1.66M | -1.09M |
| Interest Income | 87K | 2.23M | 1.56M | 366K | 3.86M | 13.73M | 13.79M | 12.73M | 13.11M |
| Interest Expense | 0 | 0 | 335K | 17.59M | 15.98M | 15.11M | 14.31M | 14.39M | 7.18M |
| Other Income/Expense | -14.43M | 2.21M | 1.03M | 89.46M | -10.85M | -53.27M | 694K | 709K | -1.04M |
| Pretax Income | -17.35M▲ 0% | -52.53M▼ 202.8% | -103.26M▼ 96.6% | -83.95M▲ 18.7% | -142.07M▼ 69.2% | -162.42M▼ 14.3% | -86.91M▲ 46.5% | -21.43M▲ 75.3% | -797.46M▲ 0% |
| Pretax Margin % | - | - | - | -438.66% | -184.36% | -87.15% | -25.8% | -4.11% | -194.63% |
| Income Tax | 0 | 21K | 6K | 37K | -6.41M | 991K | 1.03M | 1.94M | 1.38M |
| Effective Tax Rate % | 0% | -0.04% | -0.01% | -0.04% | 4.51% | -0.61% | -1.19% | -9.04% | -0.17% |
| Net Income | -17.35M▲ 0% | -52.55M▼ 202.9% | -103.27M▼ 96.5% | -83.99M▲ 18.7% | -135.66M▼ 61.5% | -163.41M▼ 20.5% | -87.94M▲ 46.2% | -23.36M▲ 73.4% | -798.84M▲ 0% |
| Net Margin % | - | - | - | -438.85% | -176.05% | -87.68% | -26.1% | -4.48% | -194.97% |
| Net Income Growth % | - | -202.93% | -96.51% | 18.67% | -61.53% | -20.45% | 46.18% | 73.43% | -932.9% |
| Net Income (Continuing) | -17.35M | -52.55M | -103.27M | -83.99M | -135.66M | -163.41M | -87.94M | -23.36M | -798.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.75▲ 0% | -2.29▼ 205.3% | -4.09▼ 78.6% | -2.77▲ 32.3% | -4.02▼ 45.1% | -4.00▲ 0.5% | -1.85▲ 53.8% | -0.47▲ 74.6% | -13.57▲ 0% |
| EPS Growth % | - | -205.33% | -78.6% | 32.27% | -45.13% | 0.5% | 53.75% | 74.59% | -745.9% |
| EPS (Basic) | -0.75 | -2.29 | -4.09 | -2.77 | -4.01 | -4.00 | -1.85 | -0.47 | - |
| Diluted Shares Outstanding | 22.99M | 22.99M | 25.25M | 30.32M | 33.98M | 40.89M | 47.52M | 50.2M | 58.85M |
| Basic Shares Outstanding | 22.99M | 22.99M | 25.25M | 30.32M | 33.84M | 40.89M | 47.52M | 50.2M | 58.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MIRM Balance Sheet
Mirum Pharmaceuticals, Inc. (MIRM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 51.98M | 119.36M | 236.35M | 166.59M | 190.22M | 387.54M | 392.79M | 549.68M | 569.44M |
| Cash & Short-Term Investments | 51.96M | 116.66M | 231.82M | 156.54M | 151.72M | 286.33M | 280.31M | 383.33M | 386.26M |
| Cash Only | 51.96M | 11.97M | 142.09M | 31.34M | 28M | 286.33M | 222.5M | 296.68M | 324.91M |
| Short-Term Investments | 0 | 104.69M | 89.73M | 125.2M | 123.72M | 0 | 57.81M | 86.64M | 61.35M |
| Accounts Receivable | 0 | 0 | 0 | 3.27M | 23.99M | 67.97M | 78.29M | 123.33M | 133.11M |
| Days Sales Outstanding | - | - | - | 62.31 | 113.65 | 133.11 | 84.82 | 86.35 | 104.76 |
| Inventory | 0 | 0 | 0 | 1.51M | 5.57M | 22.31M | 22.4M | 24.89M | 25.52M |
| Days Inventory Outstanding | - | - | - | 290.2 | 164.15 | 173.13 | 100.16 | 90.31 | 10.67 |
| Other Current Assets | 12K | 0 | 0 | 0 | 8.95M | 10.94M | 11.78M | 18.14M | 24.55M |
| Total Non-Current Assets | 0 | 27.35M | 4.51M | 128.06M | 162.68M | 259.08M | 277.97M | 293.13M | 321.48M |
| Property, Plant & Equipment | 0 | 3.73M | 3.24M | 2.55M | 2.35M | 1.99M | 9.81M | 0 | 15.06M |
| Fixed Asset Turnover | - | - | - | 7.51x | 32.86x | 93.66x | 34.33x | - | 46.88x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 18.74M | 58.95M | 252.93M | 249.82M | 260.92M | 254.15M |
| Long-Term Investments | 0 | 23.29M | 0 | 4.98M | 0 | 0 | 12.53M | 8.11M | 62.04M |
| Other Non-Current Assets | 0 | 324K | 1.27M | 101.79M | 101.38M | 4.17M | 5.81M | 24.1M | 59.74M |
| Total Assets | 51.98M▲ 0% | 146.71M▲ 182.3% | 240.86M▲ 64.2% | 294.65M▲ 22.3% | 352.91M▲ 19.8% | 646.62M▲ 83.2% | 670.75M▲ 3.7% | 842.81M▲ 25.7% | 890.92M▲ 0% |
| Asset Turnover | - | - | - | 0.06x | 0.22x | 0.29x | 0.50x | 0.62x | 0.51x |
| Asset Growth % | - | 182.27% | 64.17% | 22.33% | 19.77% | 83.23% | 3.73% | 25.65% | 82.12% |
| Total Current Liabilities | 2.45M | 13.08M | 18.46M | 42.6M | 64.73M | 87.06M | 126.55M | 205.8M | 272.82M |
| Accounts Payable | 269K | 3.35M | 3.15M | 9.17M | 8.69M | 7.42M | 14.62M | 9.61M | 59.4M |
| Days Payables Outstanding | - | 3.78K | 1.85K | 1.76K | 256.33 | 57.54 | 65.35 | 34.89 | 10.83 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.14M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 15K | 2.22M | 6.07M | 11.98M | 15.75M | 20.94M | 32.25M | 146.77M | 272.82M |
| Current Ratio | 21.22x | 9.13x | 12.80x | 3.91x | 2.94x | 4.45x | 3.10x | 2.67x | 2.67x |
| Quick Ratio | 21.22x | 9.13x | 12.80x | 3.88x | 2.85x | 4.19x | 2.93x | 2.55x | 2.55x |
| Cash Conversion Cycle | - | - | - | -1.41K | 21.47 | 248.7 | 119.62 | 141.77 | 104.6 |
| Total Non-Current Liabilities | 59.85M | 3.29M | 50.31M | 131.84M | 146.14M | 310.89M | 318.56M | 322.32M | 375.6M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 306.42M | 308.08M | 309.8M | 321.43M |
| Capital Lease Obligations | 0 | 3.25M | 2.63M | 1.9M | 1.26M | 617K | 7.97M | 7.52M | 22.76M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 59.85M | 36K | 29K | 17K | 4.53M | 3.85M | 2.51M | 5.01M | 84.22M |
| Total Liabilities | 62.3M | 16.36M | 68.77M | 174.44M | 210.87M | 397.95M | 445.11M | 528.12M | 648.42M |
| Total Debt | 0 | 3.65M | 3.26M | 2.61M | 2.19M | 308.14M | 317.76M | 319.45M | 321.43M |
| Net Debt | -51.96M | -8.32M | -138.82M | -28.73M | -25.82M | 21.82M | 95.26M | 22.77M | -3.48M |
| Debt / Equity | - | 0.03x | 0.02x | 0.02x | 0.02x | 1.24x | 1.41x | 1.02x | 1.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | 151.54x | -0.41x |
| Net Debt / EBITDA | -35.64x | - | - | - | - | - | - | 10.80x | 10.80x |
| Interest Coverage | - | - | -307.25x | -3.77x | -7.89x | -9.75x | -5.07x | -0.49x | -0.03x |
| Total Equity | -10.32M▲ 0% | 130.35M▲ 1362.7% | 172.09M▲ 32.0% | 120.21M▼ 30.1% | 142.04M▲ 18.2% | 248.67M▲ 75.1% | 225.64M▼ 9.3% | 314.69M▲ 39.5% | 242.49M▲ 0% |
| Equity Growth % | - | 1362.7% | 32.03% | -30.15% | 18.16% | 75.07% | -9.26% | 39.47% | 80.72% |
| Book Value per Share | -0.45 | 5.67 | 6.82 | 3.96 | 4.18 | 6.08 | 4.75 | 6.27 | 4.12 |
| Total Shareholders' Equity | -10.32M | 130.35M | 172.09M | 120.21M | 142.04M | 248.67M | 225.64M | 314.69M | 242.49M |
| Common Stock | 6.99M | 2K | 3K | 3K | 4K | 5K | 5K | 5K | 6K |
| Retained Earnings | -17.35M | -69.9M | -173.17M | -257.16M | -392.82M | -556.24M | -644.18M | -667.54M | -1.46B |
| Treasury Stock | 66.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -66.84M | 129K | 83K | -35K | -217K | 1.64M | -373K | 351K | -28K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MIRM Cash Flow Statement
Mirum Pharmaceuticals, Inc. (MIRM) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -373K | -39.36M | -89.08M | -132.76M | -120.14M | -70.94M | 10.32M | 55.83M | 55.83M |
| Operating CF Margin % | - | - | - | -693.69% | -155.9% | -38.07% | 3.06% | 10.71% | - |
| Operating CF Growth % | - | -10452.82% | -126.3% | -49.04% | 9.51% | 40.95% | 114.55% | 440.7% | -10033.32% |
| Net Income | -17.35M | -52.55M | -103.27M | -83.99M | -135.66M | -163.41M | -87.94M | -23.36M | -798.84M |
| Depreciation & Amortization | 0 | 324K | 623K | 975K | 3.68M | 10.83M | 23.63M | 24.24M | 25.07M |
| Stock-Based Compensation | 51K | 6.07M | 12.55M | 23.09M | 27.01M | 35.02M | 48.44M | 71.42M | 91.82M |
| Deferred Taxes | 0 | 0 | 72K | 595K | -6.58M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 12.09M | -326K | 335K | -90.41M | 12.47M | 69.26M | 3.6M | 3.24M | 519.39M |
| Working Capital Changes | 2.44M | 7.12M | 611K | 16.98M | -21.05M | -22.64M | 22.59M | -19.71M | -8.42M |
| Change in Receivables | 0 | 0 | 0 | 0 | -20.73M | -43.97M | -11.43M | -48.05M | -44.11M |
| Change in Inventory | 0 | 0 | 0 | -495K | -3.45M | -4.39M | -3.17M | -8.45M | -7.7M |
| Change in Payables | 2.45M | 10.06M | 3.68M | 22.66M | 7.64M | 30.78M | 40.31M | 50.1M | 95.61M |
| Cash from Investing | -7.5M | -127.78M | 37.87M | 48.55M | 7.7M | -107.2M | -90.13M | -23.95M | -19.39M |
| Capital Expenditures | -7.5M | -281K | -225K | -19.02M | -278K | -109K | -993K | -954K | -1.58M |
| CapEx % of Revenue | - | - | - | 99.4% | 0.36% | 0.06% | 0.29% | 0.18% | - |
| Acquisitions | 0 | 127.5M | -38.1M | -19M | -7.98M | -212.76M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -11.25M | -127.5M | 38.1M | 127M | 7.98M | -20M | -20M | 0 | -10M |
| Cash from Financing | 59.84M | 127.18M | 181.29M | 73.47M | 109.09M | 336.6M | 17.7M | 40.14M | 303.86M |
| Debt Issued (Net) | 50K | 0 | 0 | 0 | 0 | 305.3M | 0 | 0 | 0 |
| Equity Issued (Net) | 59.79M | 127.18M | 131.87M | 6.91M | 107.37M | 216.68M | 17.7M | 40.14M | 33.78M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 49.42M | 66.55M | 1.72M | -185.39M | 0 | 0 | 270.08M |
| Net Change in Cash | 51.96M▲ 0% | -39.99M▼ 177.0% | 130.12M▲ 425.3% | -10.75M▼ 108.3% | -3.34M▲ 68.9% | 158.32M▲ 4844.5% | -63.4M▼ 140.0% | 75.24M▲ 218.7% | 114.39M▲ 0% |
| Free Cash Flow | -7.87M▲ 0% | -39.64M▼ 403.5% | -89.3M▼ 125.3% | -151.78M▼ 70.0% | -120.41M▲ 20.7% | -91.05M▲ 24.4% | 9.33M▲ 110.2% | 54.87M▲ 488.0% | -172.55M▲ 0% |
| FCF Margin % | - | - | - | -793.09% | -156.26% | -48.85% | 2.77% | 10.53% | -42.11% |
| FCF Growth % | - | -403.53% | -125.26% | -69.97% | 20.67% | 24.38% | 110.25% | 488.01% | -519.15% |
| FCF per Share | -0.34 | -1.72 | -3.54 | -5.01 | -3.54 | -2.23 | 0.20 | 1.09 | 1.09 |
| FCF Conversion (FCF/Net Income) | 0.02x | 0.75x | 0.86x | 1.58x | 0.89x | 0.43x | -0.12x | -2.39x | 0.22x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 6.82M | 12.65M | 0 | 6.33M |
| Taxes Paid | 0 | 21K | 11K | 0 | 0 | 125K | 1M | 0 | 1.49M |
MIRM Key Ratios
Mirum Pharmaceuticals, Inc. (MIRM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -87.57% | -68.29% | -57.47% | -103.46% | -83.65% | -37.08% | -8.65% | -289.33% |
| Return on Invested Capital (ROIC) | -137.45% | -100.74% | -208.5% | -94.76% | -42.34% | -22.22% | -5.04% | -5.04% |
| Gross Margin | - | - | 90.06% | 83.94% | 74.76% | 75.77% | 80.71% | -103.16% |
| Net Margin | - | - | -438.85% | -176.05% | -87.68% | -26.1% | -4.48% | -194.97% |
| Debt / Equity | 0.03x | 0.02x | 0.02x | 0.02x | 1.24x | 1.41x | 1.02x | 1.02x |
| Interest Coverage | - | -307.25x | -3.77x | -7.89x | -9.75x | -5.07x | -0.49x | -0.03x |
| FCF Conversion | 0.75x | 0.86x | 1.58x | 0.89x | 0.43x | -0.12x | -2.39x | 0.22x |
| Revenue Growth | - | - | - | 302.66% | 141.85% | 80.76% | 54.74% | 8.04% |
MIRM SEC Filings & Documents
Mirum Pharmaceuticals, Inc. (MIRM) SEC filings — annual & quarterly reports (10-K, 10-Q)
MIRM Frequently Asked Questions
Mirum Pharmaceuticals, Inc. (MIRM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mirum Pharmaceuticals, Inc. (MIRM) reported $409.7M in revenue for fiscal year 2025.
Mirum Pharmaceuticals, Inc. (MIRM) grew revenue by 54.7% over the past year. This is strong growth.
Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $798.8M for fiscal year 2025.
Dividend & Returns
Mirum Pharmaceuticals, Inc. (MIRM) has a return on equity (ROE) of -8.6%. Negative ROE indicates the company is unprofitable.
Mirum Pharmaceuticals, Inc. (MIRM) had negative free cash flow of $172.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More MIRM
Mirum Pharmaceuticals, Inc. (MIRM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates